Sun Pharmaceuticals Rating: Buy- Market trends augur well for Ilumya sales in US
Mahindra CIE Rating: Buy- Strong show at the end of calendar year CY21/22e EPS up ~6/4%; TP raised to Rs 253; stock is undervalued; ‘Buy’ retained After COVID-19 disruptions in H1, … Read More